65489-03-4

Basic information

• Product Name: 1-(2-O-TOLYLOXY-ETHYL)-PIPERAZINE
• Synonyms: AKOS BC-2663;1-(2-O-TOLYLOXY-ETHYL)-PIPERAZINE;TIMTEC-BB SBB011454;1-[2-(2-Methylphenoxy)ethyl]piperazine
• CAS NO: 65489-03-4
• Molecular Formula: C₁₃H₂₀N₂O
• Molecular Weight: 220.31
• Mol File: 65489-03-4.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(2-O-TOLYLOXY-ETHYL)-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-O-TOLYLOXY-ETHYL)-PIPERAZINE(65489-03-4)
• EPA Substance Registry System: 1-(2-O-TOLYLOXY-ETHYL)-PIPERAZINE(65489-03-4)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 65489-03-4(Hazardous Substances Data)

Usage

General Description

1-(2-O-tolyloxy-ethyl)-piperazine, also known as TPIP, is a chemical compound with the molecular formula C14H22N2O. It is a piperazine derivative with a tolyloxy-ethyl group attached to the nitrogen atom. TPIP is commonly used as a building block in the synthesis of pharmaceutical compounds and biologically active molecules. It has been studied for its potential as a drug candidate for the treatment of various medical conditions, including cancer and neurological disorders. TPIP is a versatile and important chemical compound in medicinal chemistry and drug discovery research.

Upstream product

• 110-85-0 piperazine 
• 18800-32-3 1-(2-bromoethoxy)-2-methylbenzene 
• 95-48-7 ortho-cresol 

Downstream Products

• 1327128-09-5 thiophen-2-yl(4-(2-(o-tolyloxy)ethyl)piperazin-1-yl)methanone 
• 1352792-17-6 thiophen-2-yl(4-(2-(o-tolyloxy)ethyl)piperazin-1-yl)methanone hydrochloride 
• 1352792-27-8 N-(thiazol-2-yl)-2-(4-(2-(o-tolyloxy)ethyl)piperazin-1-yl)acetamide 

Relevant articles and documents

Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I)

Kv1.5 potassium channel is an efficacious and safe therapeutic target for the treatment of atrial fibrillation (AF), the most common arrhythmia that threatens human. Herein, by modifying the hit compound 7k from an in-house database, 48 derivatives were synthesized for the assay of their Kv1.5 inhibitory effects by whole cell patch clamp technique. Six compounds which showed better potency than the positive compound dronedarone were selected for the next evaluation of their drug-like properties. Compound 8 exhibited balanced solubility and permeability. It also showed acceptable pharmacodynamics profile with very low acute toxicity. Taking all these data into account, compound 8 can serve as a promising lead for the development of novel therapeutic agent for the treatment of AF.